ArticleExperimental and therapeutic medicine2010
Human MLH1 status can potentially predict cisplatin sensitivity but not microsatellite instability in head and neck squamous cell carcinoma cells.
Article in Experimental and therapeutic medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 11 citations in OpenAlex.
- Combined therapy with cisplatin and 5-AZA-2CdR modifies methylation and expression of DNA repair genes in oral squamous cell carcinoma.International journal of clinical and experimental pathology · 2022Article
- PMS2: a potential prognostic protein marker in oral squamous cell carcinoma.Medicina oral, patologia oral y cirugia bucal · 2021Article
- Review
- EBV infection is associated with histone bivalent switch modifications in squamous epithelial cells.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistance to platinum-based chemotherapy frequently poses a serious problem in the treatment of head and neck squamous cell carcinoma. In this study, we isolated cisplatin-resistant cells from a head and neck squamous cell carcinoma cell line. The mismatch repair (MMR) system is known as one of the cisplatin-resistant mechanisms. When the expression levels of hMLH1 and hMSH2, a mismatch repair gene and its gene product, were analyzed, the hMLH1 mRNA and protein expression levels were significantly decreased in the cisplatin-resistant cell lines compared with a cisplatin-sensitive cell line. In addition, the microsatellite instability (MSI) phenotype was examined for the absence of MMR. Our data support the hypothesis that hMLH1 mRNA and protein expression levels are predictors of cisplatin sensitivity, but MSI was not involved in cisplatin resistance. The status of hMLH1 predicts the sensitivity of head and neck squamous cell carcinoma to platinum-based chemotherapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.